203 related articles for article (PubMed ID: 29323537)
1. Investigational therapies targeting CD37 for the treatment of B-cell lymphoid malignancies.
Witkowska M; Smolewski P; Robak T
Expert Opin Investig Drugs; 2018 Feb; 27(2):171-177. PubMed ID: 29323537
[TBL] [Abstract][Full Text] [Related]
2. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.
Pereira DS; Guevara CI; Jin L; Mbong N; Verlinsky A; Hsu SJ; Aviña H; Karki S; Abad JD; Yang P; Moon SJ; Malik F; Choi MY; An Z; Morrison K; Challita-Eid PM; Doñate F; Joseph IB; Kipps TJ; Dick JE; Stover DR
Mol Cancer Ther; 2015 Jul; 14(7):1650-60. PubMed ID: 25934707
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD37 antibodies for chronic lymphocytic leukemia.
Robak T; Robak P
Expert Opin Biol Ther; 2014 May; 14(5):651-61. PubMed ID: 24555705
[TBL] [Abstract][Full Text] [Related]
4. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
[TBL] [Abstract][Full Text] [Related]
5. CD37 in B Cell Derived Tumors-More than Just a Docking Point for Monoclonal Antibodies.
Bobrowicz M; Kubacz M; Slusarczyk A; Winiarska M
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333768
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD37 targeted immunotherapy of B-Cell malignancies.
Payandeh Z; Noori E; Khalesi B; Mard-Soltani M; Abdolalizadeh J; Khalili S
Biotechnol Lett; 2018 Dec; 40(11-12):1459-1466. PubMed ID: 30293139
[TBL] [Abstract][Full Text] [Related]
7. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine.
Arribas AJ; Gaudio E; Napoli S; Yvon Herbaux CJ; Tarantelli C; Bordone RP; Cascione L; Munz N; Aresu L; Sgrignani J; Rinaldi A; Kwee I; Rossi D; Cavalli A; Zucca E; Stussi G; Stathis A; Sloss C; Davids MS; Bertoni F
bioRxiv; 2023 Nov; ():. PubMed ID: 38014209
[TBL] [Abstract][Full Text] [Related]
8. DuoHexaBody-CD37
Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
10. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
Bobrowicz M; Kusowska A; Krawczyk M; Zhylko A; Forcados C; Slusarczyk A; Barankiewicz J; Domagala J; Kubacz M; Šmída M; Dostalova L; Marhelava K; Fidyt K; Pepek M; Baranowska I; Szumera-Cieckiewicz A; Inderberg EM; Wälchli S; Granica M; Graczyk-Jarzynka A; Majchrzak M; Poreba M; Gehlert CL; Peipp M; Firczuk M; Prochorec-Sobieszek M; Winiarska M
Oncoimmunology; 2024; 13(1):2362454. PubMed ID: 38846084
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò I; Ormhøj M; Frigault MJ; Castano AP; Lorrey S; Bouffard AA; van Scoyk A; Rodig SJ; Shay AJ; Aster JC; Preffer FI; Weinstock DM; Maus MV
Blood; 2018 Oct; 132(14):1495-1506. PubMed ID: 30089630
[TBL] [Abstract][Full Text] [Related]
12. Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
Pagel JM; Spurgeon SE; Byrd JC; Awan FT; Flinn IW; Lanasa MC; Eisenfeld AJ; Stromatt SC; Gopal AK
Br J Haematol; 2015 Jan; 168(1):38-45. PubMed ID: 25146490
[TBL] [Abstract][Full Text] [Related]
13. CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.
Oostindie SC; van der Horst HJ; Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; VanDerMeid KR; Strumane K; Chamuleau MED; Mutis T; de Jong RN; Schuurman J; Breij ECW; Beurskens FJ; Parren PWHI; Taylor RP
Haematologica; 2019 Sep; 104(9):1841-1852. PubMed ID: 30792198
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Kroschinsky F; Middeke JM; Janz M; Lenz G; Witzens-Harig M; Bouabdallah R; La Rosée P; Viardot A; Salles G; Kim SJ; Kim TM; Ottmann O; Chromik J; Quinson AM; von Wangenheim U; Burkard U; Berk A; Schmitz N
Invest New Drugs; 2020 Oct; 38(5):1472-1482. PubMed ID: 32172489
[TBL] [Abstract][Full Text] [Related]
15. Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells.
Yu B; Mao Y; Yuan Y; Yue C; Wang X; Mo X; Jarjoura D; Paulaitis ME; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Biomaterials; 2013 Aug; 34(26):6185-93. PubMed ID: 23726226
[TBL] [Abstract][Full Text] [Related]
16. Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Rafiq S; Siadak A; Butchar JP; Cheney C; Lozanski G; Jacob NK; Lapalombella R; McGourty J; Moledor M; Lowe R; Setter B; Jones J; Flynn JM; Andritsos L; Devine S; Mo X; Jarjoura D; Tridandapani S; Algate P; Byrd JC; Muthusamy N
MAbs; 2013; 5(5):723-35. PubMed ID: 23883821
[TBL] [Abstract][Full Text] [Related]
17. Pro-apoptotic effect of an anti-CD37 scFv-Fc fusion protein, in combination with the anti-CD20 antibody, ofatumumab, on tumour cells from B-cell malignancies.
Smolewski P; Robak P; Cebula-Obrzut B; Misiewicz M; Mędra A; Majchrzak A; Witkowska M; Stromatt S; Robak T
Eur J Cancer; 2014 Oct; 50(15):2677-84. PubMed ID: 25154027
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.
Robak T
Expert Rev Hematol; 2014 Dec; 7(6):841-57. PubMed ID: 25249370
[TBL] [Abstract][Full Text] [Related]
19. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
Robak T; Robak P; Smolewski P
Curr Opin Investig Drugs; 2009 Dec; 10(12):1383-90. PubMed ID: 19943209
[TBL] [Abstract][Full Text] [Related]
20. The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Beckwith KA; Frissora FW; Stefanovski MR; Towns WH; Cheney C; Mo X; Deckert J; Croce CM; Flynn JM; Andritsos LA; Jones JA; Maddocks KJ; Lozanski G; Byrd JC; Muthusamy N
Leukemia; 2014 Jul; 28(7):1501-10. PubMed ID: 24445867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]